• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
FeaturesHealth

‘Open Humans’ platform wants to democratize your DNA for better medical research

By
Laura Lorenzetti
Laura Lorenzetti
Down Arrow Button Icon
By
Laura Lorenzetti
Laura Lorenzetti
Down Arrow Button Icon
March 24, 2015, 11:06 AM ET
<h1>DNA Rx</h1>


In 2003, a team of researchers working for the Department of Energy and the National Institutes of Health completed a 13-year long effort called the Human Genome Project. The goal of the project was, among other things, to identify and map every gene in human DNA. For a while, the scientific community has been looking at the data and wondering, "So, what's next?" 


One answer is targeted therapy, medical treatments that do not only address symptoms, but also respond to a patient's genetic makeup. 


The past couple of years have yielded breakthroughs in this field. In 2011, a team of scientists at the University of Pennsylvania effectively treated leukemia patients by engineering their own white blood cells to fight the disease. Also in 2011, researchers in Britain achieved promising results in treating the genetic disease hemophilia B by injecting patients with a re-engineered version of the gene. 2012 brought even more advancements, using targeted therapy to treat inherited blindness.


"Talk about transforming an industry," says George Day, co-director of the Mack Center at Wharton. "Big Pharma has always been pill-based," he says, meaning patients need daily dosage, whereas "gene therapy is one and done.


"I think finally after 20 years, the promise of gene therapy is starting to be realized."
<h1>DNA Rx</h1> In 2003, a team of researchers working for the Department of Energy and the National Institutes of Health completed a 13-year long effort called the Human Genome Project. The goal of the project was, among other things, to identify and map every gene in human DNA. For a while, the scientific community has been looking at the data and wondering, "So, what's next?" One answer is targeted therapy, medical treatments that do not only address symptoms, but also respond to a patient's genetic makeup. The past couple of years have yielded breakthroughs in this field. In 2011, a team of scientists at the University of Pennsylvania effectively treated leukemia patients by engineering their own white blood cells to fight the disease. Also in 2011, researchers in Britain achieved promising results in treating the genetic disease hemophilia B by injecting patients with a re-engineered version of the gene. 2012 brought even more advancements, using targeted therapy to treat inherited blindness. "Talk about transforming an industry," says George Day, co-director of the Mack Center at Wharton. "Big Pharma has always been pill-based," he says, meaning patients need daily dosage, whereas "gene therapy is one and done. "I think finally after 20 years, the promise of gene therapy is starting to be realized." Illustration: Alfred Pasieka/Getty Images

Get ready to share more than photos of your latest vacation.

A new online platform launched Tuesday allows users to share data about their genomes, gut bacteria and other biological data with scientists and researchers.

The “Open Humans Network,” backed by the Knight Foundation and Robert Wood Johnson Foundation, aims to make more data available for researchers across studies. Its goal is to democratize valuable information that study leaders have typically held secret in order to prevent access by others. The fear is that a competitor could beat them to an important discovery.

Geneticist George Church of Harvard University said that such DNA data are also valuable to gene-testing companies — those companies can profit from the data too, he said.

But the mindset of secrecy slows down important medical research that could lead to breakthroughs on anything from cancer treatments to better flu vaccines.

Open Humans hopes to break that pattern by allowing universal access to the data stored on the site by researchers on other projects. Unlike other “de-identified” data, it will come with names and contact information attached so scientists can follow up with users.

Project director Jason Bobe compares it to other tech platforms: “It’s like open-sourcing your body,” he said.

The site currently hosts three studies that users can sign up for: American Gut looks at the relationship between gut bacteria and disease; GoViral identifies what viruses are circulating during flu season in the U.S.; and the Personal Genome Project, led by Church, gathers DNA data to make connections between genomic patterns and health.

Users allow any legitimate user to access their information when they sign up, which raises potential privacy concerns. In order to sign up, participants must pass a test showing they understand the risks of sharing private health information. If hacked, the leaked information could affect a person’s access to life insurance, or long-term care coverage.

—Reuters contributed to this report.
[fortune-brightcove videoid=4109993040001]

About the Author
By Laura Lorenzetti
See full bioRight Arrow Button Icon

Latest in Features

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Features

Who owns ideas in the AI age?
MagazinePublishing
Who owns ideas in the AI age?
By Francesca CassidyApril 8, 2026
4 days ago
The Walmart billionaires next door: Quiet backlash is brewing against the heirs who remade the retailer’s hometown
MagazineWalmart
The Walmart billionaires next door: Quiet backlash is brewing against the heirs who remade the retailer’s hometown
By Jessica MathewsApril 3, 2026
9 days ago
Have a strong brand in a world of noise—it’s like having the only red T-shirt in a stadium full of white ones
MagazineVolvo
Have a strong brand in a world of noise—it’s like having the only red T-shirt in a stadium full of white ones
By Kamal AhmedApril 2, 2026
10 days ago
Ken Griffin wants to reshape Miami—and maybe American politics
MagazineKen Griffin
Ken Griffin wants to reshape Miami—and maybe American politics
By Shawn TullyMarch 31, 2026
12 days ago
The world’s consumers are ready for robotaxis. James Peng of Pony AI wants to make sure they’re riding in his
MagazineChina
The world’s consumers are ready for robotaxis. James Peng of Pony AI wants to make sure they’re riding in his
By Nicholas GordonMarch 26, 2026
17 days ago
The youngest-ever female CEO of a Fortune 500 company is fighting Trump’s cuts to keep Medicaid strong
MagazineCentene
The youngest-ever female CEO of a Fortune 500 company is fighting Trump’s cuts to keep Medicaid strong
By Diane BradyMarch 24, 2026
19 days ago

Most Popular

'This is the last warning.' Iran threatens U.S. warships after they throw down the gauntlet for winner-take-all Strait of Hormuz
Politics
'This is the last warning.' Iran threatens U.S. warships after they throw down the gauntlet for winner-take-all Strait of Hormuz
By Fortune EditorsApril 11, 2026
19 hours ago
Palantir CEO says AI ‘will destroy’ humanities jobs but there will be ‘more than enough jobs’ for people with vocational training
Future of Work
Palantir CEO says AI ‘will destroy’ humanities jobs but there will be ‘more than enough jobs’ for people with vocational training
By Fortune EditorsApril 11, 2026
1 day ago
The 'affordability economy' has created a housing market nobody predicted: Prices collapsing in the Sun Belt, soaring in the Rust Belt
Real Estate
The 'affordability economy' has created a housing market nobody predicted: Prices collapsing in the Sun Belt, soaring in the Rust Belt
By Fortune EditorsApril 11, 2026
1 day ago
Warren Buffett says 'accumulating great amounts of money' doesn’t achieve greatness—He still lives in a $31,500 Nebraska home and clipped coupons
Success
Warren Buffett says 'accumulating great amounts of money' doesn’t achieve greatness—He still lives in a $31,500 Nebraska home and clipped coupons
By Fortune EditorsApril 11, 2026
1 day ago
Navy tests Hormuz blockade as expert says U.S. military prepares for round 2 and could degrade Iran's hold over the strait to a 'manageable level'
Politics
Navy tests Hormuz blockade as expert says U.S. military prepares for round 2 and could degrade Iran's hold over the strait to a 'manageable level'
By Fortune EditorsApril 11, 2026
1 day ago
2 years ago, Saudi Arabia quietly canceled the ‘petrodollar’ deal with America that wired the world economy for 50 years. Then war broke out in Iran
Energy
2 years ago, Saudi Arabia quietly canceled the ‘petrodollar’ deal with America that wired the world economy for 50 years. Then war broke out in Iran
By Fortune EditorsApril 7, 2026
5 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.